{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.0","upperLimit":"8.0","value":"7.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"}],"units":"Participants"}],"description":"This outcome measure was defined as the time from the date of reinitiation of nilotinib treatment following loss of major molecular response (MMR) to the date of first documented achievement of MMR. Participants who did not regain MMR after reinitiation of treatment on or before the data cut-off date were censored at the date of their last available BCR-ABN PCR assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who experienced loss of major molecular response during the treatment-free remission (TFR) phase entered the nilotinib treatment re-initiation (NTRI) phase. During this phase, nilotinib treatment was re-initiated at a dose of 300 mg twice daily.","id":"OG000","title":"NTRI Phase"}],"paramType":"MEDIAN","populationDescription":"The nilotinib treatment re-initiation (NTRI) safety set included all participants who received at least one dose of study medication during the nilotinib treatment re-initiation phase.","reportingStatus":"POSTED","timeFrame":"Every 4 weeks up to Week 24, and every 12 weeks thereafter, up to Week 528","title":"Duration of Re-Initiated Nilotinib Treatment Required to Regain Major Molecular Response (MMR) After Loss of MMR","type":"SECONDARY","unitOfMeasure":"Weeks"}